Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 4, Pages 684
Publisher
MDPI AG
Online
2017-03-23
DOI
10.3390/ijms18040684
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease
- (2016) Jose Luis López-Sendón Moreno et al. JOURNAL OF NEUROLOGY
- Novel Metabolite Biomarkers of Huntington’s Disease As Detected by High-Resolution Mass Spectrometry
- (2016) Stewart F. Graham et al. JOURNAL OF PROTEOME RESEARCH
- Effects of Cannabidiol and Hypothermia on Short-Term Brain Damage in New-Born Piglets after Acute Hypoxia-Ischemia
- (2016) Hector Lafuente et al. Frontiers in Neuroscience
- In Vivo and Ex Vivo Magnetic Resonance Spectroscopy of the Infarct and the Subventricular Zone in Experimental Stroke
- (2015) Elena Jiménez-Xarrié et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Differential Effects of Delayed Aging on Phenotype and Striatal Pathology in a Murine Model of Huntington Disease
- (2014) S. J. Tallaksen-Greene et al. JOURNAL OF NEUROSCIENCE
- Towards a reproducible protocol for repetitive and semi-quantitative rat brain imaging with 18 F-FDG: Exemplified in a memantine pharmacological challenge
- (2014) Steven Deleye et al. NEUROIMAGE
- Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice
- (2014) Sara Valdeolivas et al. Neurotherapeutics
- Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression
- (2013) Geraldine T. Petr et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Mechanisms of cannabidiol neuroprotection in hypoxic–ischemic newborn pigs: Role of 5HT1A and CB2 receptors
- (2013) M. Ruth Pazos et al. NEUROPHARMACOLOGY
- Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington’s Disease: Role of CB1 and CB2 Receptors
- (2012) Sara Valdeolivas et al. ACS Chemical Neuroscience
- Evaluation of the safety and tolerability profile of Sativex®: is it reassuring enough?
- (2012) Derick Wade Expert Review of Neurotherapeutics
- Characterization of Neurophysiological and Behavioral Changes, MRI Brain Volumetry and 1H MRS in zQ175 Knock-In Mouse Model of Huntington's Disease
- (2012) Taneli Heikkinen et al. PLoS One
- 1H NMR based metabolomics of CSF and blood serum: A metabolic profile for a transgenic rat model of Huntington disease
- (2011) Kim A. Verwaest et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Role of Cannabinoids in Multiple Sclerosis
- (2011) John P. Zajicek et al. CNS DRUGS
- THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis
- (2011) Jaume Sastre-Garriga et al. Expert Review of Neurotherapeutics
- Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease
- (2011) Onintza Sagredo et al. JOURNAL OF NEUROSCIENCE RESEARCH
- Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease
- (2010) Cristina Blázquez et al. BRAIN
- The endocannabinoid system as a target for the treatment of neuronal damage
- (2010) Javier Fernández-Ruiz et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Huntington's disease: progress toward effective disease-modifying treatments and a cure
- (2010) C. D. Johnson et al. HUMAN MOLECULAR GENETICS
- Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice
- (2010) M.J. Dowie et al. NEUROSCIENCE
- Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
- (2010) Chiara Zuccato et al. PHYSIOLOGICAL REVIEWS
- Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
- (2009) Javier Palazuelos et al. BRAIN
- Emerging strategies for exploiting cannabinoid receptor agonists as medicines
- (2009) Roger G Pertwee BRITISH JOURNAL OF PHARMACOLOGY
- Cannabinoid CB2receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease
- (2009) Onintza Sagredo et al. GLIA
- A pilot study using nabilone for symptomatic treatment in Huntington's disease
- (2009) Adrienne Curtis et al. MOVEMENT DISORDERS
- The Endocannabinoid System in Huntingtons Disease
- (2008) M. Pazos et al. CURRENT PHARMACEUTICAL DESIGN
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now